Xinghai Forum: Professor Bin Hua and Juliang Zhang Discuss Advances in (Neo)Adjuvant Treatment and Personalized Strategies for Triple-Negative Breast

Xinghai Forum: Professor Bin Hua and Juliang Zhang Discuss Advances in (Neo)Adjuvant Treatment and Personalized Strategies for Triple-Negative Breast

With continuous advancements in medical research, treatment strategies for triple-negative breast cancer (TNBC) are also evolving. From June 14-16, 2024, the 5th Comprehensive Cancer Treatment Academic Conference of the Xinghai Medical Forum was held in the romantic city of Dalian. Multiple significant studies on TNBC treatment were highlighted at ASCO, including the application of platinum-based therapies, new adjuvant treatment models, intensified adjuvant treatments, and the use of immunotherapy and ADCs in (neo)adjuvant settings. Oncology Frontier invited Professor Bin Hua from Beijing Hospital and Professor Juliang Zhang  from Xijing Hospital of Air Force Medical University  discuss these latest research advancements in depth.
ISTH China’s Voice | Professor Xuefeng Wang’s Team: Single-cell sequencing of PBMCs from hemophilia A and hemophilia B patients with inhibitors reveals different immune responses to FVIII and FIX after replacement therapy

ISTH China’s Voice | Professor Xuefeng Wang’s Team: Single-cell sequencing of PBMCs from hemophilia A and hemophilia B patients with inhibitors reveals different immune responses to FVIII and FIX after replacement therapy

The 32nd International Society on Thrombosis and Haemostasis (ISTH 2024) Congress was held in Bangkok, Thailand, from June 22 to June 26, 2024. As the most influential event in the field of thrombosis and hemostasis, the ISTH Congress attracts thousands of top experts and scholars worldwide with its profound academic impact and rich content. The "ISTH China's Voices" column of Oncology Frontier-Hematology Frontier aims to showcase outstanding research achievements from the Chinese academic community at ISTH. In this issue, we present a research finding from Dr. Enhao Li of Professor Xuefeng Wang's team at Ruijin Hospital, Shanghai Jiaotong University School of Medicine. Dr. Li's oral presentation at ISTH delved into the differential immune responses to FVIII and FIX in hemophilia A (HA) and hemophilia B (HB) patients, providing valuable academic insights for the hematology field.
Professor Sifeng Tao and Hui Liu Discuss Advances in (Neo)Adjuvant Treatment and Personalized Strategies for Triple-Negative Breast Cancer

Professor Sifeng Tao and Hui Liu Discuss Advances in (Neo)Adjuvant Treatment and Personalized Strategies for Triple-Negative Breast Cancer

With continuous advancements in medical research, treatment strategies for triple-negative breast cancer (TNBC) are also evolving. From June 14-16, 2024, the 5th Comprehensive Cancer Treatment Academic Conference of the Xinghai Medical Forum was held in the romantic city of Dalian. Multiple significant studies on TNBC treatment were highlighted at ASCO, including the application of platinum-based therapies, new adjuvant treatment models, intensified adjuvant treatments, and the use of immunotherapy and ADCs in (neo)adjuvant settings. Oncology Frontier invited Professor Sifeng Tao from The Second Affiliated Hospital Zhejiang University School of Medicine and Professor Hui Liu fro
ISTH Academician’s Voices | Academician Heyu Ni: Leading Thrombosis Research and Uniting Global Chinese Scientists in Advancing International Research

ISTH Academician’s Voices | Academician Heyu Ni: Leading Thrombosis Research and Uniting Global Chinese Scientists in Advancing International Research

The 32nd International Society on Thrombosis and Haemostasis (ISTH 2024) Congress was held in Bangkok, Thailand, from June 22 to June 26, 2024. As the most influential event in the field of thrombosis and hemostasis, the ISTH Congress attracts thousands of top experts and scholars from around the world with its profound academic impact and rich content. During this prestigious event, Oncology Frontier-Hematology Frontier had the honor of interviewing Academician Heyu Ni from the Canadian Academy of Health Sciences, who also served as the Chair of the Joint ISTH Congress and Global Chinese Thrombosis and Hemostasis Conference. In this interview, Academician Ni shared his extensive academic experience and unique insights, providing us with valuable academic reflections and perspectives. We have organized this interview into an article for our readers.
CDL (China Diabetes and Liver Disease Co-management Action Plan) Literature Monthly Review—June 2024, Issue 17

CDL (China Diabetes and Liver Disease Co-management Action Plan) Literature Monthly Review—June 2024, Issue 17

Diabetes and liver disease are prevalent chronic conditions in China. They often interact in terms of pathogenesis, clinical manifestations, and treatment targets, acting as mutual risk factors. Joint management can alleviate the disease burden. To support the development of co-management of diabetes and liver disease in China, this journal, in collaboration with the CDL (China Diabetes and Liver Disease Co-management Action Plan), launches the CDL Literature Monthly Review column. Each month, we share relevant research on the mechanisms and treatment advancements of diabetes combined with liver disease, inviting experts in the field to provide commentary. This aims to offer insights and assistance to researchers and frontline medical professionals in scientific research and clinical practice.
Case Sharing: A Case of Hepatic Sinusoidal Obstruction Syndrome Induced by Combined Drug and Alcohol Use

Case Sharing: A Case of Hepatic Sinusoidal Obstruction Syndrome Induced by Combined Drug and Alcohol Use

Hepatic sinusoidal obstruction syndrome (HSOS), also known as hepatic veno-occlusive disease, is a common secondary vascular liver disease caused by various factors leading to damage to sinusoidal endothelial cells, resulting in sinusoidal obstruction and hepatic congestion. Clinically, it primarily presents with abdominal distension, liver pain, rapid ascites accumulation, hepatomegaly, and jaundice, which can lead to severe liver dysfunction, multi-organ failure, and even death. Professor Qingchun Fu's team from the Shanghai Public Health Clinical Center shares a clinical case and their experience in diagnosing and treating a patient with HSOS induced by combined drug and alcohol use.
Advances in Clinical Research on Curing Chronic Hepatitis B in NAs-treated Populations by Professor Li Li

Advances in Clinical Research on Curing Chronic Hepatitis B in NAs-treated Populations by Professor Li Li

Recently, the 25th National Conference on Traditional Chinese Medicine and Hepatobiliary Diseases organized by the Chinese Association of Traditional Chinese Medicine was successfully held in Chongqing. The conference invited distinguished TCM masters, academicians, renowned TCM experts, and hepatology specialists from across the country to deliver academic reports, focusing on the hot and challenging issues in the diagnosis and treatment of liver diseases with TCM. At the conference, Professor Li Li from Beijing Hospital of Traditional Chinese Medicine, presented a report titled "Latest Advances in the Clinical Cure of Chronic Hepatitis B." The following is a summary of the report for our readers.
Xinghai Forum: Professors Baoliang Guo and Guiying Xu Share Research Progress on ctDNA Monitoring in Breast Cancer

Xinghai Forum: Professors Baoliang Guo and Guiying Xu Share Research Progress on ctDNA Monitoring in Breast Cancer

Circulating tumor DNA (ctDNA) testing allows for continuous dynamic monitoring of tumor genetic variations without relying on tissue samples. This liquid biopsy technology has been widely used in clinical breast cancer research for prognosis and treatment evaluation, but there are still no standards for ctDNA testing, including population selection, testing frequency, and testing methods. At the recent 5th Comprehensive Cancer Treatment Academic Conference of the Dalian Xinghai Medical Forum, Oncology Frontier invited Professor Baoliang Guo from The Second Affiliated Hospital of Harbin Medical University, Professor Guiying Xu from Jilin Cancer Hospital to discuss the application of ctDNA monitoring in breast cancer.
Xinghai Forum: Professors Pengfei Qiu and Hao Wang Share Research Progress on ctDNA Monitoring in Breast Cancer

Xinghai Forum: Professors Pengfei Qiu and Hao Wang Share Research Progress on ctDNA Monitoring in Breast Cancer

Circulating tumor DNA (ctDNA) testing allows for continuous dynamic monitoring of tumor genetic variations without relying on tissue samples. This liquid biopsy technology has been widely used in clinical breast cancer research for prognosis and treatment evaluation, but there are still no standards for ctDNA testing, including population selection, testing frequency, and testing methods. At the recent 5th Comprehensive Cancer Treatment Academic Conference of the Dalian Xinghai Medical Forum, Oncology Frontier invited Professor Pengfei Qiu from Shandong Cancer Hospital, and Professor Hao Wang fro
the CHANGEABLE Phase II Study: Niraparib + HX008 for Safe and Effective Treatment of Germline BRCA1/2 Mutated MBC Patients

the CHANGEABLE Phase II Study: Niraparib + HX008 for Safe and Effective Treatment of Germline BRCA1/2 Mutated MBC Patients

In recent years, the rapid development of immunotherapy and targeted therapy has continuously updated the treatment strategies for metastatic breast cancer (MBC) patients. PARP inhibitors and immune checkpoint inhibitors, developed based on the concept of synthetic lethality, have become important treatment options for HER2- MBC patients, yet there remains a significant unmet need for treatment. Recently, at the ASCO 2024 conference, a collaborative team led by Professors Zhen Hu , Jian Zhang, and Yun Liu from Fudan University Shanghai Cancer Center shared the results of the Phase II CHANGEABLE study. This study revealed new hope for the combination of the PARP inhibitor niraparib and the PD-1 monoclonal antibody HX008 in MBC patients with germline DDR gene mutations. At ASCO 2024, Oncology Frontier interviewed Professor Jian Zhang to discuss the background, results, and significance of this study. The key insights are summarized below: